Kenvue Inc.

Biopharma financing during the fourth quarter of 2024 totaled $16.8bn from 251 deals. Of those, 60 reached $100m or more. The follow-on public offering (FOPO) and venture financing categories tied for

As the first healthcare company to report fourth-quarter and full-year 2024 financial results, Johnson & Johnson (J&J) had the opportunity to set the tempo for earnings season. With its stock

Private investment in public equity (PIPE) transactions continue to be an important means of fundraising for publicly traded biopharmaceutical companies while the financial markets continue to recover

Use of Kenvue Inc. ’s Nicorette QuickMist nicotine replacement therapy (NRT) device provides “statistically significant and fast relief” of urges to vape, according to a recently published study fund